Tag: Bortezomib

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Bortezomib

Daratumumab Treatment Advancements in Newly Diagnosed Multiple Myeloma

Added to Collection on: 2024-06-03 16:07:51

Tags for this article:

Orphan drugs
Immunosuppressants
Antineoplastic drugs
Pyrazines
Teratogens
Multiple myeloma
CD38
Carfilzomib
Lenalidomide
Bortezomib
Cereblon E3 ligase modulator
Minimal residual disease
Dexamethasone

Click the tags to see associated articles and topics

View Article Details
Dose Modification and Premedications Aid in Tolerability of NDMM Therapy

Added to Collection on: 2024-06-07 21:19:14

Tags for this article:

Orphan drugs
Pyrazines
Multiple myeloma
Therapy
Bortezomib

Click the tags to see associated articles and topics

View Article Details
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

Added to Collection on: 2024-06-21 22:47:30

Tags for this article:

Orphan drugs
Isatuximab
Multiple myeloma
Pomalidomide
Daratumumab
Lenalidomide
Dexamethasone
Bortezomib
Selinexor
Elotuzumab

Click the tags to see associated articles and topics

View Article Details
BENEFIT Trial Results Show Quadruplet Regimen for NDMM TI May Require Weighing ...

Added to Collection on: 2024-06-22 11:23:43

Tags for this article:

Orphan drugs
Multiple myeloma
Bortezomib
Isatuximab
Lenalidomide
Peripheral neuropathy
Minimal residual disease
Progression-free survival
Dexamethasone
AUSTIN
James A. Davis

Click the tags to see associated articles and topics

View Article Details
Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups

Added to Collection on: 2024-07-01 13:06:37

Tags for this article:

Orphan drugs
Multiple myeloma
Belantamab mafodotin
Daratumumab
Bortezomib
Antibody-drug conjugate
Lenalidomide
Monomethyl auristatin F
Proteasome inhibitor
Dexamethasone
Cereblon E3 ligase modulator
B-cell maturation antigen

Click the tags to see associated articles and topics

View Article Details
Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or ...

Added to Collection on: 2024-07-03 15:46:15

Tags for this article:

Orphan drugs
Multiple myeloma
Daratumumab
Elotuzumab
Carfilzomib
Lenalidomide
Ciltacabtagene autoleucel
Pomalidomide
Cereblon E3 ligase modulator
Bortezomib
CAR T cell
B-cell maturation antigen

Click the tags to see associated articles and topics

View Article Details
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for ...

Added to Collection on: 2024-11-15 10:22:01

Tags for this article:

Orphan drugs
B-cell maturation antigen
Belantamab mafodotin
Multiple myeloma
Daratumumab
Antibody-drug conjugate
Pomalidomide
Seagen
Bortezomib
Monomethyl auristatin F
Isatuximab
Daratumumab/hyaluronidase
gsk plc

Click the tags to see associated articles and topics

View Article Details
FDA Accepts GSK's Biologics License Application of Blenrep for Relapsed or Refractory ...

Added to Collection on: 2024-12-02 19:42:08

Tags for this article:

Orphan drugs
Multiple myeloma
Pomalidomide
Bortezomib
Belantamab mafodotin
Dexamethasone
Monomethyl auristatin F
Biologics license application
Daratumumab/hyaluronidase
Elotuzumab

Click the tags to see associated articles and topics

View Article Details
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of ...

Added to Collection on: 2025-01-22 08:59:35

Tags for this article:

Orphan drugs
Isatuximab
Multiple myeloma
Carfilzomib
Pomalidomide
Lenalidomide
CD38
Dexamethasone
Sanofi
Bortezomib
Daratumumab
Selinexor

Click the tags to see associated articles and topics

View Article Details
China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

Added to Collection on: 2025-01-31 22:36:35

Tags for this article:

Orphan drugs
Immunosuppressants
Antineoplastic drugs
Pyrazines
Teratogens
Isatuximab
Multiple myeloma
Lenalidomide
Bortezomib
Progression-free survival
VRD
Cereblon E3 ligase modulator
Dexamethasone

Click the tags to see associated articles and topics

View Article Details